Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRS Timing with Immunotherapy in NSCLC Brain Metastases
NCT04650490Phase 2Withdrawn
- Sponsor
- Duke University
- Start
- Mar 2023
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) and brain metastasis (BM), sponsored by Duke University. Planned start Mar 2023; status: withdrawn.
02
Conditions
non-small cell lung cancer (NSCLC)brain metastasis (BM)
Beyond the preview
Go deeper on NCT04650490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04650490.